SCHEMBL2388976

SCHEMBL2388976

CCc1sc2ccccc2c1C

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 4/20 0.46
CNR1 P21554 2/20 0.46
GPR3 P46089 1/20 0.46
LOXL2 Q9Y4K0 1/20 0.46
L3MBTL1 Q9Y468 2/20 0.42
ATM Q13315 1/20 0.42
ALDH1A1 P00352 2/20 0.41
KDM4E B2RXH2 2/20 0.41
RAB9A P51151 2/20 0.41
MEN1 O00255 1/20 0.41
PKM P14618 1/20 0.41
MAPK1 P28482 1/20 0.41
KMT2A Q03164 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
TAS1R3 Q7RTX0 1/20 0.41
TAS1R1 Q7RTX1 1/20 0.41
PRNP P04156 1/20 0.40
RXFP1 Q9HBX9 1/20 0.40
HSD11B1 P28845 1/20 0.40
PTPN1 P18031 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2387916 0.84 CNR2 (0.49) CNR2CNR1GPR3LOXL2L3MBTL1
SCHEMBL586085 0.82 GPR3 (0.44) CNR2CNR1GPR3LOXL2ALDH1A1
SCHEMBL719251 0.82 GPR3 (0.44) CNR2CNR1GPR3LOXL2L3MBTL1
SCHEMBL2702753 0.82 LOXL2 (0.63) CNR2CNR1GPR3LOXL2ALDH1A1
SCHEMBL1035524 0.82 LOXL2 (0.48) CNR2CNR1GPR3LOXL2ALDH1A1
SCHEMBL13973068 0.80 TAS1R3 (0.45) CNR2CNR1GPR3LOXL2L3MBTL1
SCHEMBL14045624 0.79 CNR2 (0.46) CNR2CNR1GPR3LOXL2L3MBTL1
SCHEMBL4775813 0.79 LOXL2 (0.42) CNR2CNR1GPR3LOXL2ALDH1A1
SCHEMBL7100115 0.79 LOXL2 (0.42) CNR2CNR1GPR3LOXL2L3MBTL1
SCHEMBL13328626 0.79 CNR1 (0.50) CNR2CNR1GPR3LOXL2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3675847-B1 SPIROCYCLE COMPOUNDS AND METHODS OF MAKING AND USING SAME H LUNDBECK AS (DK) 2023-07-12 EP disclosed
US-20230011568-A1 ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING ORGANOMETALLIC COMPOUND, AND ELECTRONIC APPARATUS INCLUDING ORGANIC LIGHT-EMITTING DEVICE SAMSUNG DISPLAY CO., LTD. (KR) 2023-01-12 US disclosed
US-20230008665-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES UNIVERSAL DISPLAY CORPORATION (US) 2023-01-12 US disclosed
WO-2021261969-A1 PREPARATION METHOD FOR NOVEL COMPOUND 홀로스메딕 주식회사 2021-12-30 WO disclosed
WO-2020065408-A1 SULFOMALEIMIDE-BASED LINKERS AND CORRESPONDING CONJUGATES PIERRE FABRE MEDICAMENT (FR) 2020-04-02 WO disclosed
CN-105992808-B Use of magnetic nanoparticles for depleting aromatic compounds in oil 综合E&P丹麦股份有限公司 2018-10-19 CN disclosed
US-9969943-B2 Use of magnetic nanoparticles for depletion of aromatic compounds in oil MAERSK OLIE OG GAS A/S (DK) 2018-05-15 US disclosed
WO-2017062581-A1 COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING CFTR PROTEOSTASIS THERAPEUTICS, INC. (US) 2017-04-13 WO disclosed
CN-105992808-A Use of magnetic nanoparticles for depleting aromatic compounds in oil 马士基橄榄和气体公司 2016-10-05 CN disclosed
US-20160272898-A1 USE OF MAGNETIC NANOPARTICLES FOR DEPLETION OF AROMATIC COMPOUNDS IN OIL TOTAL E&P DANMARK A/S (DK) 2016-09-22 US disclosed
US-20080182854-A1 4-Amino-5-Cyanopyrimidine Derivatives OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2008-07-31 US disclosed
EP-1923451-A1 METHOD FOR DESULFURIZATION OF HYDROCARBON OIL JAPAN ENERGY CORPORATION (JP) 2008-05-21 EP disclosed
EP-1740574-B1 4-AMINO-5-CYANOPYRIMIDINE DERIVATIVES OTSUKA PHARMA CO LTD (JP) 2007-06-27 EP disclosed
US-20070099955-A1 3-PIPERIDINYLISOCHROMAN-5-OLS AS DOPAMINE AGONISTS AVENTIS PHARMACEUTICALS INC. (US) 2007-05-03 US disclosed
US-20070099955-A1 3-PIPERIDINYLISOCHROMAN-5-OLS AS DOPAMINE AGONISTS AVENTIS PHARMACEUTICALS INC. (US) 2007-05-03 US disclosed
US-20070078120-A1 Novel piperidine derivative DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2007-04-05 US disclosed
US-20070037851-A1 Inhibits binding of CCR3 ligands such as eotaxins to their target cells; inhibits physiological effects of binding; therapeutic and prophylactic agents for asthma, rhinitis, dermatitis, urticaria, conjunctivitis, inflammatory bowel; tissue infiltration of eosinophils, basophils, activated T cells TEIJIN LIMITED, A JAPANESE BODY CORPORATE (JP) 2007-02-15 US disclosed
CN-1914298-A Method of desulfurizing hydrocarbon oil JAPAN ENERGY CORP (JP) 2007-02-14 CN disclosed
US-20070032525-A1 Piperidine derivatives having ccr3 antagonism TEIJIN LIMITED, A JAPANESE BODY CORPORATE (JP) 2007-02-08 US disclosed
EP-1715025-A1 METHOD OF DESULFURIZING HYDROCARBON OIL JAPAN ENERGY CORPORATION (JP) 2006-10-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070078120-A1 Novel piperidine derivative LDLR, PRMT5, MSR1 CNR2 147/4885CNR1 42/4885GPR3 221/4885
US-20230011568-A1 ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING ORGANOMETALLIC COMPOUND, AND ELECTRONIC APPARATUS INCLUDING ORGANIC LIGHT-EMITTING DEVICE L1CAM, AP1M1, AP2M1 CNR2 2930/4885CNR1 2613/4885GPR3 4025/4885
US-20080182854-A1 4-Amino-5-Cyanopyrimidine Derivatives ADORA2A, ADORA1, ADORA3 CNR2 69/4885CNR1 56/4885GPR3 59/4885
US-20070032525-A1 Piperidine derivatives having ccr3 antagonism CCR3, CCR1, CCR4 CNR2 98/4885CNR1 74/4885GPR3 13/4885
US-20070037851-A1 Inhibits binding of CCR3 ligands such as eotaxins to their target cells; inhibits physiological effects of binding; therapeutic and prophylactic agents for asthma, rhinitis, dermatitis, urticaria, conjunctivitis, inflammatory bowel; tissue infiltration of eosinophils, basophils, activated T cells CCR3, CCR1, CCR4 CNR2 154/4885CNR1 123/4885GPR3 29/4885
US-20070099955-A1 3-PIPERIDINYLISOCHROMAN-5-OLS AS DOPAMINE AGONISTS DRD3, DRD2, DRD4 CNR2 205/4885CNR1 103/4885GPR3 116/4885
US-20230008665-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES ICOSLG, OCIAD2, OCIAD1 CNR2 1757/4885CNR1 1901/4885GPR3 633/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.